Type 1 diabetes treatment enters transformative phase with disease-modifying therapies and innovation pipeline

Recent advances in drug development are shifting the landscape of type 1 diabetes from symptomatic management to disease modification and potential insulin independence, driven by novel therapies like Sanofi’s Tzield and emerging cell-based approaches. Type 1 diabetes research is moving…













